Slider image 1

The DolPHIN 2 team

Slider image 2

Project Manager Helen leading a stakeholder mapping exercise

Slider image 3

Visiting the Gugulethu site, Cape Town

Slider image 4

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

Welcome to DolPHIN2

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

The project will investigate whether dolutegravir is superior to efavirenz-based regimens (the current standard of care within sub-Saharan Africa) at preventing mother to child transmission of HIV for women who begin HIV treatment in the third trimester of pregnancy. We aim to establish high-quality evidence and operational guidance for the use of dolutegravir (DTG) in late pregnancy through:

- A multi-site clinical trial – taking place in Uganda and South Africa

- Qualitative studies – assessing the acceptability of dolutegravir and the reasons for late presentation in pregnancy

- A Pharmacoeconomic study – assessing the cost effectiveness of dolutegravir against the standard of care in South Africa and Uganda.

Read more about DolPHIN 2 , find out about our team and access the latest resources on PMTCT and the project.

DolPHIN 2 is funded by UNITAID.


Twitter & News Feed

DolPHIN-2 presents primary outcome analysis at CROI 2019

On March 4th 2019, at the CROI conference in Seattle, USA, Chief Investigator Professor Saye Khoo presented the primary outcome analy...

March 13, 2019 14:59

DolPHIN 2 Trial Manager and Trial Monitor to visit Cape Town site

The DolPHIN 2 trial opened for recruitment in our South African site last month. 

In light of this, the Trial Manager and

February 05, 2018 12:11

The External Monitor: The eyes and ears of the Sponsor!

Let me introduce myself first: I am Angela Colbers, working as a research assistant and post-doc at the Department of Pharmacy of the Radb...

January 25, 2018 14:25

The first participant has been recruited to the DolPHIN 2 trial!

On 22nd January 2018, our South African site opened to recruitment with the very first participant recruited into the DolPHIN-2...

January 25, 2018 12:37

The DolPHIN 2 Site Initiation Visits

On the 11th to 13th October 2017, we undertook the Site Initiation Visit (SIV) for the DolPHIN-2 study in Kampala, U...

November 29, 2017 16:08

The Liverpool team sets off for Uganda: IDI Site Initiation Visit

Today marks an important step in the set-up of the DolPHIN 2 trial, as key members of the Liverpool team make their way to Uganda for a Si...

October 09, 2017 13:51

DolPHIN-2 Consortium meeting, 27th -29th March 2017

After months of teleconferences, the  DolPHIN-2 project team finally came face to face at our first consortium meeting. 
At t...

May 03, 2017 13:34

To sign up to our newsletter, please enter your details below: